The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy

[1] Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol 2014; 2014:437971.10.1155/2014/437971Search in Google Scholar

[2] Sherman SI. Thyroid carcinoma. Lancet 2003; 361(9356):501-511.10.1016/S0140-6736(03)12488-9Search in Google Scholar

[3] Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998; 83 (12):2638-2648.10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1Search in Google Scholar

[4] Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 2001; 130 (6): 921-930.10.1067/msy.2001.118370Search in Google Scholar

[5] Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86 (4):1447-1463.10.1210/jcem.86.4.7407Search in Google Scholar

[6] Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009; 19(11):1167-1214.10.1089/thy.2009.0110Search in Google Scholar

[7] Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26(8): 879-885.10.1007/s00268-002-6612-1Search in Google Scholar

[8] Wartofsky L, Van Nostrand D. Radioiodine treatment of well-differentiated thyroid cancer. Endocrine 2012; 42(3): 506-513.10.1007/s12020-012-9729-5Search in Google Scholar

[9] McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002; 34(7-8): 554-564.10.1080/078538902321117760Search in Google Scholar

[10] Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005; 1: 32-40.10.1038/ncpendmet0020Search in Google Scholar

[11] Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172(10):799-809.10.1001/archinternmed.2012.402Search in Google Scholar

[12] Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011; 150(6): 1250-1257.10.1016/j.surg.2011.09.013Search in Google Scholar

[13] Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20(2):135-146.10.1089/thy.2009.0311Search in Google Scholar

[14] Rongen HA, Hoetelmans RM, Bult A, van Bennekom WP. Chemiluminescence and immunoassays. J Pharm Biomed Anal 1994; 12(4):433-462.10.1016/0731-7085(94)80027-8Search in Google Scholar

[15] Koszegi T. Immunoluminometric detection of human procalcitonin. J Biochem Biophys Methods 2002; 53(1-3):157-64.10.1016/S0165-022X(02)00104-5Search in Google Scholar

[16] Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104: 947-953.Search in Google Scholar

[17] Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab 1976; 42(2): 395-398.10.1210/jcem-42-2-395177443Search in Google Scholar

[18] Carayon P, Thomas-Morvan C, Castanas E, Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 1980; 51(4):915-920.10.1210/jcem-51-4-9157419673Search in Google Scholar

[19] Clark OH, Gerend PL, Goretzki P, Nissenson RA. Characterization of the thyrotropin receptoradenylate cyclase system in neoplastic human thyroid tissue. J Clin Endocrinol Metab 1983; 57(1):140-147.10.1210/jcem-57-1-1406304132Search in Google Scholar

[20] Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3’, 5’-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 1988; 66(6):1158-1165.10.1210/jcem-66-6-11582836470Search in Google Scholar

[21] Goretzki PE, Frilling A, Simon D, Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 1990; 118:48-63.10.1007/978-3-642-83816-3_62173080Search in Google Scholar

[22] Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84(11): 3877-3885.10.1210/jc.84.11.3877Search in Google Scholar

[23] Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977; 56(3):171-196.10.1097/00005792-197705000-00001Search in Google Scholar

[24] Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008; 93(4): 1167-1169.10.1210/jc.2007-2228Search in Google Scholar

[25] Cooper DS. TSH suppressive therapy: an overview of long-term clinical consequences. Hormones 2010; 9(1):57-59.10.14310/horm.2002.1259Search in Google Scholar

[26] Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81(12):4318-4323.Search in Google Scholar

[27] Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8(9):737-744.10.1089/thy.1998.8.737Search in Google Scholar

[28] Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16(12):1229-1242.10.1089/thy.2006.16.1229Search in Google Scholar

[29] Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97 (5): 418-428.10.1016/0002-9343(94)90321-2Search in Google Scholar

[30] Lang BH, Chow SM, Lo CY, Law SC, Lam KY. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg 2007; 246(1): 114-121.10.1097/01.sla.0000262785.46403.9bSearch in Google Scholar

[31] Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004; 135(2):139-148.10.1016/S0039-6060(03)00384-2Search in Google Scholar

[32] Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92(7): 2610-2615.10.1210/jc.2006-256617426094Search in Google Scholar

[33] Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992; 164 (6): 658-661.10.1016/S0002-9610(05)80729-9Search in Google Scholar

[34] Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995; 170 (5): 467-470.10.1016/S0002-9610(99)80331-6Search in Google Scholar

[35] Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992; 164 (6): 671-676.10.1016/S0002-9610(05)80732-9Search in Google Scholar

[36] Voutilainen PE, Multanen MM, Leppäniemi AK, Haglund CH, Haapiainen RK, Franssila KO. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 2001; 11 (10): 953-957.10.1089/10507250175321102811716043Search in Google Scholar

[37] Staunton MD. Thyroid cancer. A multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 1994; 20 (6): 613-621. 32 Niveen A. Abo-Touk, Dalia H. ZayedSearch in Google Scholar

[38] Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994; 78(5): 1028-1033.Search in Google Scholar

[39] Gullu S, Altuntas F, Dincer I, Erol C, Kamel N. Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction. Eur J Endocrinol 2004; 150(5): 655-661.10.1530/eje.0.150065515132721Search in Google Scholar

[40] Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81(3): 1232-1236.Search in Google Scholar